BioNTech will assess multiple vaccine candidates featuring known malaria targets such as the circumsporozoite protein (CSP), as well as new antigens.
By ANTHONY KITIMO German biotech company BioNTech SE has announced the start of its malaria project, which aims to develop safe, effective and sustainable malaria vaccine supply solutions in Africa. BioNTech wants to build on its success in developing a Covid-19 vaccine (in conjunction with Pfizer) by developing the first vaccine for malaria based on…